Breast Cancer Res Treat by Banegas, Matthew P. et al.
Heterogeneity of breast cancer subtypes and survival among
Hispanic women with invasive breast cancer in California
Matthew P. Banegas, PhD, MPH, MS1,*, Li Tao, MD, MS, PhD2, Sean Altekruse, DVM, MPH,
PhD, DACVPM3, William F. Anderson, MD, MPH1, Esther M. John, PhD, MSPH2,4, Christina
A. Clarke, PhD, MPH2,4, and Scarlett L. Gomez, PhD2,4
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
2Cancer Prevention Institute of California, Fremont CA
3Surveillance Research Program, Division of Cancer Control and Population Sciences, National
Cancer Institute, Bethesda, MD
4Division of Epidemiology, Department of Health Research and Policy, Stanford University School
of Medicine, Stanford, CA
Abstract
Purpose—There are limited data regarding breast cancer subtypes among Hispanic women. The
current study assessed the distribution and prognosis of molecular subtypes defined by joint
expression of the hormone receptors (HR; estrogen and progesterone) and human epidermal
growth factor receptor 2 (HER2).
Methods—Using California Cancer Registry data, we identified Hispanic women diagnosed with
invasive breast cancer from 2005–2010. Breast cancer subtypes were defined as HR+/HER2−, HR
+/HER2+, HR−/HER2+, and HR−/HER2− (triple negative). We estimated breast cancer subtype
frequencies and used polytomous logistic regression, Kaplan Meier survival plots and Cox
regression to examine differences in relation to demographic and clinical characteristics.
Results—Among 16,380 Hispanic women with breast cancer, HR+/HER− subtype was most
common (63%), followed by triple negative (16%), HR+/HER2+ (14%) and HR−/HER2+ (8%).
Women in lower SES neighborhoods had greater risk of triple negative and HR−/HER2+ subtypes
relative to HR+/HER2− (p<0.05). Hispanic women with triple negative and HR−/HER2+ tumors
experienced poorer survival than those with HR+/HER− tumors. Breast cancer-specific mortality
increased with decreasing SES, relative to the highest SES quintile, from HR=1.38 for quintile 4
to HR=1.76 for quintile 1 (lowest SES level).
Conclusion—Our findings indicate that Hispanic women residing in low SES neighborhoods
had significantly increased risk of developing and dying from HR− than HR+ breast cancers.
Similar patterns of subtype frequency and prognosis among California Hispanic women and
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studies of other racial/ethnic groups underscore the need to better understand the impact of SES on
risk factor exposures that increase the risk of breast cancer subtypes with poor prognosis.
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Introduction
Hispanic women may be prone to developing breast cancer molecular subtypes (defined by
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2)) associated with poor prognosis, such as ER−/PR−, and triple negative
(ER−/PR−/HER2−) breast cancers [1–3]. Studies among Hispanics point to a 20%–40%
increased risk of developing triple negative and ER−/PR− breast cancers, compared to non-
Hispanic white women [3,2]. Women diagnosed with ER−/PR− or triple negative tumors
have significantly greater risk of death than more favorable prognosis subtypes (i.e., ER
+/PR+) [4,5]. Thus, defining the population-based distribution of breast cancer subtypes
among Hispanic women provides information of clinical, prognostic and therapeutic value.
However, only two studies have examined the patterns of breast cancer subtypes among
Hispanic women [6,7]. Hines and colleagues assessed breast tumors of 69 Hispanic women
[6], and found that the four most prevalent subtypes were ER+/PR+/HER2− (41%), triple
negative (17%), ER−/PR−/HER2+ (15%) and ER+/PR+/HER2+ (13%). Ortiz et al. showed
a similar subtype distribution among 663 women with breast cancer in Puerto Rico, and
reported a higher risk of death for triple negative and ER+/PR+/HER2+ tumors, compared to
the ER+/PR+/HER2− subtype [7]. To expand on this work, data from the California Cancer
Registry (CCR) on 16,380 Hispanic women diagnosed with invasive breast cancer were
used to characterize the molecular subtypes defined by joint hormone receptor (HR) and
HER2 status. Our objective was to conduct a large, population-based assessment of the
distribution and survival by breast cancer subtype and examine associations with
demographic and clinical attributes.
Methods
Study population
We obtained data from the CCR on all Hispanic female California residents aged 25 years
and older, diagnosed with a first primary invasive breast cancer between 2005–2010. Patient
sociodemographic information included age at diagnosis, race/ethnicity, birthplace,
insurance status, marital status and residential address at diagnosis. Race/ethnicity and
birthplace data are abstracted from medical records or death certificates [8]. The North
American Association of Central Cancer Registries Hispanic Identification Algorithm
(NHIA) was used to improve the classification of Hispanic ethnicity [9]. Patient clinical
information included American Joint Committee on Cancer (AJCC) stage, tumor grade,
tumor size, lymph node involvement, tumor metastasis and first course of treatment
(surgery, chemotherapy and radiation).
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Nativity—Patient nativity was classified as previously described [10], based on: (1) cancer
registry-based data from medical records and/or death certificates and (2) imputation using
the first five digits of the patient’s social security number (SSN), for those with unknown
birthplace (34.5%). SSN digits are linked to the state and year of issuance, from which
nativity was imputed as follows: Women who received their SSN before age 21 years were
considered United States (U.S.)-born, whereas those who received their SSN on or after age
21 years as foreign-born. The age threshold was determined and validated based on a prior
cohort of Hispanic cancer patients [11].
Neighborhood socioeconomic status (SES) and Hispanic enclave—Each
patient’s residential address at diagnosis was geocoded to a census block group. Participants
with incomplete residential address information (7.3%) were assigned an SES value based
on their county of residence. Neighborhood SES was determined based on an index that
incorporates 2000 Census (for cases diagnosed in 2005) and 2006–2010 American
Community Survey data (for cases diagnosed after 2005) on education, occupation,
unemployment, household income, poverty, rent, and house values [22]. Hispanic enclave
was based on 2000 Census variables (% linguistically isolated, % linguistically isolated who
speak Spanish, % speaking limited English, % speaking limited English who spoke Spanish,
% recent immigrants, % Hispanic, % foreign-born), developed via principal components
analysis. Participants were assigned to a neighborhood SES quintile and Hispanic enclave
quintile based on the distribution of each variable across California block groups.
Breast cancer subtype definition—A detailed description of the methods used for
classification of breast cancer subtypes has been published elsewhere [12]. Based on joint
tumor expression of ER, PR, and HER2, as described in the pathology record, breast cancers
were classified into four distinct subtype categories: HR+/HER2− was defined as ER+ or PR
+ and HER2+; HR+/HER2+ as ER+ or PR+ and HER2+; HR−/HER2+ as ER− and PR− and
HER2+; and triple negative as ER−, PR− and HER2− [13,14,4,15–17]. Participants missing
the tumor marker information needed to assign to a subtype were excluded (n=3,253
(16.6%)).
Statistical analysis
Associations between Breast Cancer Subtypes and Patient Attributes—
Adjusted polytomous regression models were used to estimate odds ratios (ORs) and 95%
confidence intervals (CIs) by sociodemographic and clinical attributes for triple negative,
HR+/HER2+ and HR−/HER2+ versus HR+/HER2− subtypes. Tests for trend were
considered statistically significant at p≤0.05.
Kaplan-Meier survival curves depicting time from diagnosis to death were calculated for
triple negative, HR+/HER2+ and HR−/HER2+ versus HR+/HER2− subtypes. Surviving
Participants were censored at the time of last known follow-up. Wilcoxon rank order test
was used to test homogeneity of survival by subtype (SAS Institute v 9.3, Cary, NC).
Adjusted Cox proportional hazard modeling was performed to estimate the risk of death
from breast cancer for all subtypes adjusted for patient sociodemographic and clinical
characteristics. Survival time, in months, was defined as time from diagnosis to whichever
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of the following occurred first: death from breast cancer, last known contact, death due to
other causes, or end of study follow-up (December 31, 2010). We tested the proportionality
assumption using scaled Schoenfeld residuals. AJCC stage levels were included in the
models as a stratifying variable, allowing the underlying hazard function to vary by stage.
Results
HR+/HER2− was the most common subtype (62.6%), followed by triple negative (15.6%),
HR+/HER2+ (13.8%) and HR−/HER2+ (8.1%) (Table 1). Over 50% of breast cancers were
diagnosed among foreign-born Hispanics, overall and within each subtype, compared to
U.S.-born Hispanics. Women in the lowest SES and highest Hispanic enclave
neighborhoods comprised the greatest proportions of participants among all breast cancer
subtypes.
Association between Breast Cancer Subtypes and Patient Attributes
Foreign-born Hispanic women were significantly more likely than U.S.-born Hispanic
women to be diagnosed with HR−/HER2+ versus HR+/HER2− breast cancer (OR=1.17,
95% CI:1.02–1.35); other subtypes did not differ by nativity (Table 2). Compared to women
living in the highest SES neighborhoods, those in lower SES neighborhoods had a 1.32–1.42
fold greater risk of triple negative (p<0.05) and 1.17–1.43 fold greater risk of HR−/HER2+
relative to HR+/HER2− breast cancer (p<0.05). Hispanic women aged 45–49 years had a
lower risk of the triple negative (OR=0.72, 95% CI:0.60–0.87) and HR−/HER2+ (OR=0.59,
95% CI:0.47–0.75) subtypes, compared to women aged 50–54 years.
Breast Cancer-Specific Survival and Mortality by Breast Cancer Subtype
Breast cancer-specific survival significantly differed between tumor subtypes (p<0.0001;
Figure 1). Over the approximately 5.5 years of follow-up, Hispanic women with triple
negative and HR−/HER2+ breast cancer had the lowest probability of survival. After
multivariate adjustment (Table 3), Hispanic women diagnosed with triple negative breast
cancer were 4-times more likely to die from the disease compared to those diagnosed with
the HR+/HER2− subtype (HR=4.05, 95% CI:3.35–4.90). Overall, the risk of death from
breast cancer followed a step-wise pattern by SES, such that the risk of death from breast
cancer increased as a woman’s neighborhood SES level decreased; compared to quintile 5
(highest SES), HRs were 1.38 (95%CI:0.98–1.94) for quintile 4 and 1.76 (95% CI:1.25–
2.49) for quintile 1.
For U.S.-born Hispanic women, the risk of breast cancer-specific mortality was significantly
greater for all subtypes compared to HR+/HER2− tumors (Table 4), whereas, among
foreign-born Hispanic women, only those diagnosed with triple negative and HR−/HER2+
subtypes had significantly increased risk of death from breast cancer.
Discussion
Our study is among the first, certainly the most comprehensive with 16,380 participants,
population-based analyses of breast cancer subtypes among U.S. Hispanic women. These
results confirm and extend emerging patterns for the molecular breast cancer subtypes.
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Similar to other racial/ethnic groups [18,13,19,20], residence in a low SES neighborhood
was significantly associated with an increased risk of diagnosis and dying from HR−/
HER2+ and triple negative breast cancers. Foreign-born Hispanics were at greater risk of
diagnosis with HR−/HER2+, compared to U.S.-born Hispanics. The risk of death from triple
negative breast cancer was substantial, as both U.S.- and foreign-born Hispanic women
diagnosed with this subtype had an approximately 4-fold greater risk of death than those
with HR+/HER2− breast cancer.
Although our case-only analyses cannot speak directly to cancer etiology or risk, these data
underscore the potential impact of SES, a social determinant of health, on risk factors that
may be etiologically important in increasing women’s risk of developing poor prognostic
breast cancer subtypes. For instance, women of low SES status, or residing in low SES
neighborhoods, may have lower access to and consume fewer healthy foods (i.e., vegetables
and nutrient-rich foods), fewer opportunities to engage in physical activity, and higher levels
of obesity [21,22], which studies indicate are associated with increased risk of ER− [23–25]
or triple negative breast cancers [26]. Moreover, low SES may be related to younger age at
first birth and lack of breastfeeding [27,28], factors associated with an elevated risk of triple
negative or basal-like breast cancers [29–31].
Importantly, if socioeconomic differences play a role in the risk of developing certain tumor
subtypes, then the breast cancer-specific mortality disadvantage observed among Hispanic
and other racial/ethnic women may be partly due to the intrinsic aggressiveness of the tumor
subtype, and the more commonly recognized factors associated with low SES or living in
low SES neighborhoods [32]. Consistent with studies among other racial/ethnic groups
[33,4,34,5], our study confirms the adverse characteristics of certain breast cancers, such
that compared to the HR+/HER2− subtype, Hispanic women diagnosed with HR+/HER2+,
HR−/HER2+, and triple negative subtypes had significantly greater risk of death.
While our study adds valuable information on breast cancer subtypes among Hispanic
women, it has some limitations. Tumor subtype information was missing for approximately
16.6% of potentially eligible participants, although the magnitude and direction of biases
related to missing data are unknown. We did not have individual-level data on income or
education; nevertheless, neighborhood-level measures may capture information on
environmental factors that occur as a result of its socioeconomic condition and deprivation
[20]. The distribution of breast cancer subtypes among Hispanic women in California may
not reflect distributions among other U.S. Hispanic women; accordingly, our findings may
be most generalizable to women of primarily Mexican descent, the largest Hispanic
subgroup in California [35]. The imputation method used to classify nativity is subject to
error and may have led to some misclassification; however, most participants (about 65%)
were classified based on cancer registry birthplace data, previously shown to have high
accuracy [11,36]. Similarly, Hispanic ethnicity may be subject to misclassification [37,38],
although classification should have improved with application of a registry-wide algorithm
[9]. While Hispanics are a diverse population, we could not include information on Hispanic
origin because it was missing for approximately 40% of participants. Breast cancer-specific
survival analyses are subject to the accuracy of the underlying cause of death code, which
has been shown to be 84–90% accurate [39,40]. Lastly, those tumor characteristics
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associated with aggressive breast cancer subtypes, including HR− and younger age at
diagnosis, are also associated with interval-detected cancers, which may lead to length bias
and lower survival than screen-derived cancers [41,42].
Conclusion
In the largest population-based study of breast cancer subtypes among U.S. Hispanic women
conducted to date, we found that residing in a low SES neighborhood was significantly
associated with increased risk of developing and dying from HR− breast cancers. Foreign-
born women were at greater risk of HR−/HER2+ tumors, although nativity was not
associated with other subtypes. Similarity in the distribution and prognosis of breast cancer
subtypes among California Hispanic women and previous studies in other racial/ethnic
groups underscores the need to understand how sociodemographic factors, such as SES,
contribute to the distinct patterns of breast cancer subtype incidence and mortality among
women of all racial/ethnic backgrounds.
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Table 4
Breast cancer-specific mortality by Hispanic nativity
Breast cancer subtype U.S.-born Hispanic Foreign-born Hispanic
Deaths HR [95% CI] Deaths HR [95% CI]
HR+/HER2− 138 Ref. 207 Ref.
Triple negative 153 4.38 (3.23–5.95) 204 4.10 (3.20–5.26)
HR+/HER2+ 66 1.57 (1.11–2.22) 67 0.93 (0.67–1.31)
HR−/HER2+ 69 3.22 (2.25–4.61) 89 1.91 (1.41–2.58)
Notes. Cox models were adjusted for socioeconomic status (quintiles), Hispanic enclave (quintiles), age at diagnosis (continuous), marital status
(married, never married, previously married), insurance status (private, public, uninsured, unknown), tumor size (continuous), lymph node (yes/no),
tumor grade (low/high/unknown) and first course of treatment (surgery, chemotherapy, and radiation therapy); AJCC stage levels I–IV and
unknown was included as a stratifying variable. Bold text signifies statistically significant associations Abbreviations: Ref.=Referent category;
HR=hazard ratio; CI=confidence interval.
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